Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50 versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50 versus RENESE.
HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50 vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle via mechanisms involving interference with calcium ion movement and possibly nitric oxide release. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (hydralazine 50 mg/hydrochlorothiazide 50 mg) orally twice daily, maximum 2 tablets daily.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Hydralazine: 2-8 hours (acetylator phenotype dependent; slow acetylators up to 8h, fast acetylators 1-2h). Hydrochlorothiazide: 6-15 hours (mean 10h).
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Hydralazine: 80% renal (mainly as metabolites, 1-2% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged) via organic anion transporters.
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic